英文名稱(chēng) | Siponimod Hemifumarate | BAF-312 Hemifumarate |
---|---|
中文名稱(chēng) | 辛波莫德半富馬酸鹽 |
CAS號(hào) | 1234627-85-0 |
分子式 | C29H35F3N2O3·1/2C4H4O4 |
分子量 | 574.63 | 516.61(free) |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
5 mg | 3-5days | ¥1166.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥1800.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Siponimod Hemifumarate | BAF-312 Hemifumarate |
---|---|
中文名稱(chēng) | 辛波莫德半富馬酸鹽 |
CAS號(hào) | 1234627-85-0 |
分子式 | C29H35F3N2O3·1/2C4H4O4 |
分子量 | 574.63 | 516.61(free) |
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research.
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
PMID: 30621015 PMCID: PMC6356776 DOI: 10.3390/cells8010024
Prospects of siponimod in secondary progressive multiple sclerosis.
PMID: 30038666 PMCID: PMC6050809 DOI: 10.1177/1756286418788013